Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.
Rifaquat RahmanLorenzo TrippaEudocia Quant LeeIsabel C Arrillaga-RomanyGeoffrey FellMehdi TouatChristine McCluskeyJennifer WileySarah GaffeyJan DrappatzMary R WelchEvanthia GalanisManmeet S AhluwaliaHoward ColmanLouis Burt NaborsJaroslaw HepelHeinrich ElinzanoDavid SchiffUgonma N ChukwuekeRameen BeroukhimLakshmi NayakJ Ricardo McFaline-FigueroaTracy T BatchelorMikael L RinneThomas J KaleyChristine Lu-EmersonIngo K MellinghoffWenya Linda BiOmar ArnaoutPier Paolo PeruzziDaphne A Haas-KoganShyam TanguturiDaniel CagneyAyal A AizerLisa DohertyMaria LavalleeBrittany Fisher-LongdenShanna DowlingJack GeduldigFiona WatkinsonWilliam PisanoSeth MalinowskiShakti RamkissoonSandro SantagataDavid M MeredithE Antonio ChioccaDavid A ReardonBrian M AlexanderKeith L LigonPatrick Yung WenPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
The INSIGhT design enabled efficient simultaneous testing of three experimental agents using a shared control arm and adaptive randomization. Two investigational arms had superior PFS compared with the control arm, but none demonstrated an OS benefit. The INSIGhT design may promote improved and more efficient therapeutic discovery in glioblastoma. New arms have been added to the trial.